University of Miami Miller School of Medicine Division of Hepatology.
Ann Hepatol. 2017 Sep-Oct;16(5):704-706. doi: 10.5604/01.3001.0010.2709.
Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-line drug. Evidence is building up in favor of fibrates, which are available for off-label use.
熊去氧胆酸是原发性胆汁性胆管炎的一线治疗药物。然而,有一部分患者未能显示出生化应答。对于这些患者,需要辅助治疗。奥贝胆酸被有条件批准为二线药物。越来越多的证据支持纤维酸类药物,这些药物可用于标签外使用。